Figure 6

Migration of cMSCs to a skin lesion and draining lymph nodes. (a) Scheme of treatment with CM-Dil-stained cMSCs in PBS control mice and OVA-induced AD mice. Mice were immunized with either PBS or OVA/Alum on days 0, 7, and 14 and epicutaneously sensitized with either PBS or OVA patches on day 21 for 1 week. On day 28, CM-DiI-stained cMSCs were intravenously injected into PBS control mice and AD mice. (b) Mice were killed on day 31, and skin and lungs were harvested. The cMSCs were detected in the lung and OVA-induced skin lesion. (c) OVA patches were treated on only the left side of the skin. At 3 days after CM-DiI-stained cMSCs injection, more cMSCs were detected in the left-side axillary lymph node than the right-side lymph node. CM-DiI-labeled cMSCs were counted in high-powered-field (HPF, × 400). Similar results were obtained in two independent experiments. *P<0.001. Scale bar=100 μm in all photomicrographs